Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 306

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 306
---
 in EU while seeking FDA approval in US. Thus, near -termrevenue potential, subject to regulatory approval. (ii) High growth prospects:In addition to oxygen and glucose monitoring, Profusa’s biosensor technology and AI monitoring is a true platform with meaningful revenue growth prospects. The Lumee Oxygen product is ready to be launched in the EU without further regulatory approval. (iii) Proven and experienced management team that is positioned to successively lead New Profusa after the Merge:Profusa is led by Ben Hwang, PhD and co -founder. Ben has a team that has been working effectively together for more than nine years. (iv) Technology that is more than a single application and has the potential to be a platform:The Profusa biosensor platform is clinically important, consumer -friendlyplatform which measures an individual’s biochemistry that is easy to use, cost -effective, and provides the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users while collecting actionable data potentially for clinical trial and pharmaceutical development. Additional product applications include lactate, sodium, CO 2and ethanol monitoring (v) Ready to go public with a substantial infrastructure and with minimal cash needs to meet milestones:Profusa is based in the U.S. with global prospects and investor interest. Profusa plans to manage operations the U.S. while manufacturing with contractors or partners regionally. (vi) Strong Investor Support:Profusa has raised over $70 million in capital to date in the private markets and over $30 million in non -dilutivefunding by DARPA and NIH demonstrating broad based interest. Strategic, global investors and potential partners have also demonstrated interest in providing financial support. • Profusa’s post -closing condition.The NorthView Board also considered factors such as Profusa’s outlook, financial plan and debt structure, taking into consideration the fact that, after consummation of the Merger, Profusa will have approximately $15 million of cash on its balance sheet (which condition was subsequently waived on the condition that the combined company is able to meet Nasdaq’s minimum listing requirements), positioning it to execute its plan to: (i)Ramp up operations to produce sensors, readers and launch its AI platform (ii)Complete pivotal studies and obtain approval of the Lumee Oxygen product in the US. File for FDA approval of the Lumee CGM product. (iii)Build commercial resources and operational capabilities (iv)Commercialize the Lumee Oxygen product and prepare for and execute commercial